跳至主要内容
临床试验/NCT05067114
NCT05067114已完成不适用

Solutions for Atrial Fibrillation Edvocacy (SAFE) Improving Awareness and Access to Atrial Fibrillation Screening for Detection and Referral for Treatment

American Pharmacists Association Foundation1 个研究点 分布在 1 个国家目标入组 650 人开始时间: 2021年9月3日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
650
试验地点
1
主要终点
Completion of atrial fibrillation screenings by pharmacists

研究概览

简要总结

The aim of this demonstration project is to create an additional access point in the community at local pharmacies for atrial fibrillation screening, detection, and referral to physicians for follow-up and initiation of evidence-based therapy when appropriate.

详细描述

The APhA Foundation will implement the Solutions for Atrial Fibrillation Edvocacy (SAFE) demonstration project integrating atrial fibrillation (Afib) screening, detection, and referral services as a routine component of care in community-based pharmacies. The SAFE solution is designed to improve awareness about Afib, increase access to screening and education opportunities related to Afib, and offer a team-based approach to care that will ultimately improve public health outcomes.

This multi-site study will utilize community pharmacies to identify patients at-risk for Afib through point-of-care patient encounters, proactive patient profile reviews, risk assessment tools, and AliveCor's FDA-cleared EKG technology.

As part of their usual and customary care, pharmacists can identify patients potentially at-risk for Afib through routine patient encounters, proactive patient profile reviews, and subsequent discussions with the patient. Identified patients will then be asked to complete a stroke risk assessment which will help determine the patient's risk level. The pharmacist will utilize the results from the stroke risk assessment to educate the patient on why these factors could add risk, why it's important to monitor these factors, and how the patient can work to reduce or improve upon certain modifiable risk factors. All patients will be educated about the risks of Afib and the importance of future monitoring based on their risk level.

Patients will then be offered the opportunity to utilize the AliveCor EKG technology to capture an EKG reading at the point-of-care. This FDA-cleared device is easy for patients to use and a pharmacy team member will be available to guide the patient to ensure proper use. Patients who are identified as having an abnormal heart rhythm, based on their EKG reading, will be referred to their physician for evaluation and follow-up. Pharmacists will follow-up with the patients that were referred to the physician to facilitate the transition of care and inquire about confirmation of Afib and initiation of treatment. Coordination and communication among patients, pharmacists, and physicians is the foundation of this patient-centered team-based care approach.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Any person at least 18 years of age
  • Person who is able to present to a pharmacist for usual and customary care

排除标准

  • Persons who are pregnant
  • Persons who are lacking in capacity
  • Persons who have a pacemaker or implantable cardioverter defibrillator (ICD) or other implanted electronic devices

结局指标

主要结局

Completion of atrial fibrillation screenings by pharmacists

时间窗: September through December 2021

Number of Afib screening tests performed in the pharmacy

Abnormal rhythm detections identified by pharmacists

时间窗: September through December 2021

Number of abnormal rhythm detections identified by AliveCor KardiaMobile technology

Physician referrals made by pharmacists

时间窗: September through December 2021

Number of physician follow-up referrals made by the pharmacist

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Solutions for Atrial Fibrillation Edvocacy (SAFE) | 临床试验